Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JPLSG-AML-20 pediatric AML MRD risk-stratification and gemtuzumab ozogamicin trial
jRCTs041210015Phase 3Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 3-year disease-free survival rate. Started May 2021; status: recruiting.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCTs041210015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210015.